Stock listing
NASDAQ:PLYX Polaryx Therapeutics, Inc. Stock
Home listing (NASDAQ) of Polaryx Therapeutics, Inc.
Follow Polaryx Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:PLYX
$1.33 USD -0.28 (-17.4%)
Close on Nov 20, 2026
- Day range
- $1.30 – $1.56 USDNov 20, 2026
- Volume
- 49,399 sharesNov 20, 2026
- Market cap
- $66.30M USDAt the close on Nov 20, 2026 · price × 49.85M shares outstanding
- Traded on an average day
- $74,853 USDMedian day 25,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PLYX · Home | $1.33 USD | -0.28 (-17.4%) | 49,399 | $1.51 | $1.56 | $1.301 | $1.61 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PLYX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.33 | -0.28 | -17.4% | $1.51 | $1.56 | $1.301 | 49,399 | |
| $1.61 | +0.01 | +0.6% | $1.65 | $1.68 | $1.61 | 22,333 | |
| $1.60 | -0.07 | -4.2% | $1.67 | $1.671 | $1.58 | 30,656 | |
| $1.67 | -0.10 | -5.6% | $1.75 | $1.76 | $1.67 | 14,855 | |
| $1.77 | -0.11 | -5.9% | $1.88 | $1.88 | $1.77 | 9,213 | |
| $1.88 | -0.07 | -3.6% | $1.91 | $1.945 | $1.88 | 9,877 | |
| $1.95 | +0.08 | +4.3% | $1.90 | $1.95 | $1.90 | 7,024 | |
| $1.87 | -0.07 | -3.6% | $1.98 | $1.98 | $1.865 | 14,728 | |
| $1.94 | +0.14 | +7.8% | $1.82 | $1.94 | $1.80 | 30,646 | |
| $1.80 | +0.06 | +3.4% | $1.74 | $1.87 | $1.738 | 23,545 | |
| $1.74 | -0.06 | -3.3% | $1.75 | $1.80 | $1.70 | 60,160 | |
| $1.80 | +0.07 | +4.0% | $1.79 | $1.84 | $1.76 | 11,120 | |
| $1.73 | -0.02 | -1.1% | $1.725 | $1.78 | $1.69 | 24,895 | |
| $1.75 | 0.00 | 0.0% | $1.76 | $1.84 | $1.72 | 30,241 | |
| $1.75 | -0.11 | -5.9% | $1.86 | $1.89 | $1.75 | 32,570 | |
| $1.86 | -0.03 | -1.6% | $1.83 | $1.89 | $1.83 | 15,385 | |
| $1.89 | +0.01 | +0.5% | $1.86 | $1.91 | $1.82 | 14,704 | |
| $1.88 | +0.06 | +3.3% | $1.83 | $1.91 | $1.822 | 14,872 | |
| $1.82 | -0.03 | -1.6% | $1.92 | $1.92 | $1.755 | 27,514 | |
| $1.85 | -0.09 | -4.6% | $1.90 | $1.90 | $1.84 | 43,000 | |
| $1.94 | 0.00 | 0.0% | $1.85 | $1.99 | $1.85 | 15,600 | |
| $1.94 | +0.03 | +1.6% | $1.89 | $1.94 | $1.85 | 13,300 | |
| $1.91 | -0.01 | -0.5% | $1.87 | $1.93 | $1.83 | 8,100 | |
| $1.92 | +0.04 | +2.1% | $1.89 | $1.92 | $1.84 | 29,300 | |
| $1.88 | -0.07 | -3.6% | $1.92 | $2.03 | $1.87 | 19,500 | |
| $1.95 | -0.02 | -1.0% | $1.94 | $1.97 | $1.88 | 42,600 | |
| $1.97 | +0.03 | +1.5% | $1.91 | $2.05 | $1.91 | 16,600 | |
| $1.94 | -0.07 | -3.5% | $1.98 | $2.05 | $1.91 | 14,800 | |
| $2.01 | +0.01 | +0.5% | $1.99 | $2.01 | $1.97 | 16,400 | |
| $2.00 | 0.00 | 0.0% | $2.00 | $2.03 | $1.98 | 11,000 | |
| $2.00 | -0.09 | -4.3% | $2.04 | $2.04 | $1.86 | 160,700 | |
| $2.09 | -0.01 | -0.5% | $2.09 | $2.10 | $2.00 | 11,400 | |
| $2.10 | +0.03 | +1.4% | $2.07 | $2.14 | $2.07 | 5,800 | |
| $2.07 | -0.01 | -0.5% | $2.05 | $2.15 | $2.04 | 40,100 | |
| $2.08 | +0.06 | +3.0% | $2.03 | $2.08 | $1.98 | 20,800 | |
| $2.02 | -0.05 | -2.4% | $2.05 | $2.06 | $1.97 | 59,000 | |
| $2.07 | 0.00 | 0.0% | $2.05 | $2.12 | $2.02 | 14,800 | |
| $2.07 | +0.03 | +1.5% | $2.05 | $2.08 | $2.00 | 31,000 | |
| $2.04 | -0.05 | -2.4% | $2.09 | $2.14 | $2.01 | 16,500 | |
| $2.09 | -0.05 | -2.3% | $2.11 | $2.14 | $2.07 | 13,400 | |
| $2.14 | 0.00 | 0.0% | $2.12 | $2.15 | $2.03 | 28,100 | |
| $2.14 | -0.01 | -0.5% | $2.19 | $2.19 | $2.04 | 54,600 | |
| $2.15 | +0.01 | +0.5% | $2.11 | $2.15 | $2.08 | 25,190 | |
| $2.14 | +0.10 | +4.9% | $2.06 | $2.168 | $2.04 | 32,086 | |
| $2.04 | -0.10 | -4.7% | $2.09 | $2.21 | $2.02 | 81,400 | |
| $2.14 | +0.11 | +5.4% | $2.06 | $2.14 | $2.05 | 27,600 | |
| $2.03 | -0.02 | -1.0% | $2.04 | $2.16 | $2.02 | 28,000 | |
| $2.05 | +0.03 | +1.5% | $2.06 | $2.06 | $1.98 | 17,100 | |
| $2.02 | +0.01 | +0.5% | $2.00 | $2.04 | $1.97 | 25,100 | |
| $2.01 | +0.02 | +1.0% | $2.00 | $2.09 | $2.00 | 14,500 | |
| $1.99 | -0.09 | -4.3% | $2.08 | $2.08 | $1.99 | 17,400 | |
| $2.08 | +0.06 | +3.0% | $2.08 | $2.12 | $2.01 | 23,300 | |
| $2.02 | +0.02 | +1.0% | $1.98 | $2.04 | $1.97 | 14,300 | |
| $2.00 | +0.01 | +0.5% | $2.00 | $2.05 | $1.90 | 39,700 | |
| $1.99 | -0.05 | -2.5% | $2.05 | $2.07 | $1.98 | 21,100 | |
| $2.04 | +0.06 | +3.0% | $2.00 | $2.07 | $1.97 | 32,800 | |
| $1.98 | -0.03 | -1.5% | $2.01 | $2.05 | $1.93 | 86,000 | |
| $2.01 | -0.05 | -2.4% | $2.10 | $2.12 | $1.99 | 41,400 | |
| $2.06 | -0.05 | -2.4% | $2.11 | $2.14 | $1.97 | 86,300 | |
| $2.11 | +0.02 | +1.0% | $2.09 | $2.16 | $2.04 | 67,100 | |
| $2.09 | +0.10 | +5.0% | $2.10 | $2.10 | $1.97 | 112,900 | |
| $1.99 | +0.12 | +6.4% | $1.90 | $2.10 | $1.90 | 107,100 | |
| $1.87 | -0.20 | -9.7% | $2.08 | $2.10 | $1.85 | 285,900 | |
| $2.07 | -0.07 | -3.3% | $2.14 | $2.15 | $2.03 | 108,500 | |
| $2.14 | -0.02 | -0.9% | $2.11 | $2.20 | $2.01 | 55,600 |
- Ticker
- NASDAQ:PLYX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 20, 2026
Polaryx Therapeutics Highlights Participation in NCL Scientific Conference and NTSAD Imagine & Believe Event
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 33 slides
Latest news
Polaryx Therapeutics Highlights Participation in NCL Scientific Conference and NTSAD Imagine & Believe Event
Nov 20, 2026
Closed $1.33 (-17.4%) on Nov 20, 2026
Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200
Nov 9, 2026
Closed $1.94 (+7.8%) on Nov 9, 2026
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
Sep 1, 2026
Closed $1.98 (-1.5%) on Sep 1, 2026
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
Aug 25, 2026
Closed $1.99 (+6.4%) on Aug 25, 2026
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
May 28, 2026
Closed $3.05 (+21.5%) on May 28, 2026
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
Apr 23, 2026
Closed $5.32 (-3.4%) on Apr 23, 2026
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
Apr 21, 2026
Closed $5.27 (-7.5%) on Apr 21, 2026
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
Apr 15, 2026
Closed $6.46 (-0.2%) on Apr 15, 2026
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
Apr 1, 2026
Closed $7.60 (+0.5%) on Apr 1, 2026
Polaryx Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 18 in all · newest Nov 20, 2026 · oldest 2026
- Decks
- 2 decks · latest November 2026
Where Polaryx Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PLYX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:PLYX | BOATS | United States | USD |
Valuation
Price/book 8.7× against a median of 2.7×: the highest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $57.86M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 8.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.66
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Polaryx Therapeutics, Inc. · NASDAQ:PLYX | US$66.30M | US$57.86M | n/a | n/a | n/a | 8.7× | n/a | 0.0× | 1.66 |
| ABIONYX Pharma SA · EURONEXT:ABNX | US$68.36M | US$55.53M | n/a | 12.4× | n/a | 4.0× | −136.6% | 1.0× | n/a |
| Cingulate Inc. · NASDAQ:CING | US$67.48M | US$1.21B | n/a | n/a | n/a | 3.3× | n/a | 56.0× | 1.41 |
| Energenesis Biomedical Co., Ltd. · TWSE:6657 | US$67.22M | US$47.02M | n/a | 203× | n/a | 3.1× | n/a | 0.0× | n/a |
| MediciNova, Inc. · NASDAQ:MNOV | US$67.11M | US$38.45M | n/a | 41.1× | n/a | 1.6× | n/a | 0.0× | 0.56 |
| Dicot Pharma AB · OMXSTO:DICOT | US$66.56M | US$44.51M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | n/a |
| Cardiff Oncology, Inc. · NASDAQ:CRDF | US$66.34M | US$32.82M | n/a | 58.7× | n/a | 2.4× | n/a | 0.0× | 1.32 |
| PMV Pharmaceuticals, Inc. · NASDAQ:PMVP | US$66.17M | −US$36.25M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.43 |
| Gossamer Bio, Inc. · NASDAQ:GOSS | US$65.57M | US$55.23M | n/a | 0.7× | n/a | n/a | −159.5% | n/a | 1.56 |
| Tenaya Therapeutics, Inc. · NASDAQ:TNYA | US$65.32M | US$1.38M | n/a | 0.5× | n/a | 1.2× | n/a | 0.1× | 2.42 |
| Atara Biotherapeutics, Inc. · NASDAQ:ATRA | US$64.49M | US$64.14M | n/a | 16.2× | n/a | n/a | −368.6% | n/a | 1.43 |
| Median of the others | US$66.45M | US$45.76M | 16.2× | 2.7× | −159.5% | 0.0× | 1.43 |
Forecasts
3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.18 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Alex Yang | CEO and Chair of the Board |
| G. Michael Landis | Chief Financial Officer |
| Minsu Kang | Vice President, Clinical Development and Regulatory Affairs |
| Eddy Zhu | Chief CMC Officer |
| Shrijay Vijayan | Chief Scientific and Business Development Officer |
| Will Charlton | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Alex Yang | CEO and Chair of the Board |
| Charles Ryan | Director |
| Francis A. Braun | Director |
| Mitchel Berger | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −5.8% |
| Q2 2026 | Aug 13, 2026 · After close | +4.0% |
| Q1 2026 | May 15, 2026 · Before open | −21.7% |
| Q4 2025 | Mar 24, 2026 · Before open | +16.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 33 slides | November 2026 |
| Investor Presentation (October 2026) | Investor deck | 33 slides | October 2026 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Research and development | 6.27M | 2.81M | 2.77M |
| Selling, general and administrative | 1.55M | 1.54M | 1.01M |
| Operating income | -7.82M | -4.35M | -3.78M |
| Income before tax | -8.98M | -30.4M | -3.78M |
| Net income | -8.98M | -30.4M | -3.78M |
| Earnings per share, basic | -0.20 | -0.89 | -0.02 |
| Earnings per share, diluted | -0.20 | -0.89 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | 5.14M | 4.62M | 2.00K |
| Current assets | 5.17M | 5.00M | 2.31M |
| Total assets | 5.17M | 5.00M | 2.31M |
| Accounts payable | 470.0K | 72.0K | 473.0K |
| Current liabilities | 605.0K | 289.0K | 1.04M |
| Total debt | 128.0K | ||
| Total liabilities | 605.0K | 289.0K | 1.04M |
| Shareholders' equity | 4.57M | 4.71M | 1.28M |
| Shares outstanding | 47.3M | 41.2M | 189.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash from operations | -3.94M | -2.57M | -173.0K |
| Capital spending | 0 | 0 | 0 |
| Free cash flow | -3.94M | -2.57M | -173.0K |
| Cash from financing | 4.47M | 7.19M | 128.0K |
| Change in cash | 522.0K | 4.62M | -45.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Sep 11, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Sep 1, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Jul 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jul 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 28, 2026 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Jul 24, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 21, 2026 | Management or board change | SEC |
| 8-K · Current report | Jul 17, 2026 | Current report | SEC |
All 36 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 8-K · Current report | May 28, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 10-K · Annual report | Mar 23, 2026 | Annual report | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 5, 2026 | Big-stake notice | SEC |
| 424B4 · Prospectus | Feb 2, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 30, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Jan 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 29, 2026 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Jan 28, 2026 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Jan 27, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 27, 2026 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jan 13, 2026 | Offer document | SEC |
| S-1 · Registration statement | Nov 20, 2025 | Offer document | SEC |
| C-U | Oct 31, 2025 | Other filings | SEC |
| C-U | Oct 27, 2025 | Other filings | SEC |
| C/A | Oct 1, 2025 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Sep 18, 2025 | Offer document | SEC |
| C | Sep 3, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Aug 5, 2025 | Offer document | SEC |
Cap table
Built by 6ix from Polaryx Therapeutics, Inc.’s releases · as of Oct 31, 2026
- Common shares
- 49,845,993
- Fully diluted
- 49,845,993
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 49,845,993 | Oct 31, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 31, 2026 | 49,845,993 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Francis A Braun III Other companies: ITG, Inc. (Director · Since at least Jul 1, 2026); Elite Express Holding Inc. (Director · Since at least Aug 20, 2025); SHF Holdings, Inc. (Director · Since at least Aug 7, 2025) | Director · Since at least Jan 29, 2026 |
| Charles Ryan Other companies: Quince Therapeutics, Inc. (President · Since at least Sep 1, 2023); Neurotrope Inc (Director · Nov 24, 2020 – Dec 1, 2020 · Past) | Director · Since at least Jan 29, 2026 |
| Alex Yang | CEO and Chair of the Board · Since at least Sep 1, 2026 |
| Andrew John O | Chief Investment Officer · Since at least Jan 29, 2026 |
| Eddy Zhu | Chief CMC Officer · Since at least Nov 4, 2026 |
| Francis A. Braun | Director · Since at least Feb 5, 2026 |
| G. Michael Landis | Chief Financial Officer · Since at least Nov 5, 2026 |
| Minsu Kang | Vice President, Clinical Development and Regulatory Affairs · Since at least Mar 12, 2026 |
| Mitchel Berger | Director · Since at least Jan 29, 2026 |
| Shrijay Vijayan | Chief Scientific and Business Development Officer · Since at least Mar 12, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Will Charlton | Chief Medical Officer · Since at least Sep 1, 2026 |
Log in to ask 6ix AI your own questions about Polaryx Therapeutics, Inc.